AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17470584 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily Record of Severity of Problems (DRSP) scores using the standard method
Number of subjects: 697
Study 17470584 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily Record of Severity of Problems (DRSP) scores using the alternative method
Number of subjects: 697
Study 17470584 — intervention group
Group type: EXPERIMENTAL
Intervention: Abbreviated seven-item DRSP version
Number of subjects: 697
Study 14709941 — intervention group
Group type: EXPERIMENTAL
Intervention: Milnacipran
Number of subjects: 0
Study 14709941 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine
Number of subjects: 0
Study 11488789 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine alone
Number of subjects: 262
Study 11488789 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadruple therapy (ranitidine, colloidal bismuth subcitrate, metronidazole, and tetracycline)
Number of subjects: 262
Study 11488789 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 262
Study 9873262 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh platelets tested within 4 hours of collection
Number of subjects: 48
Study 9873262 — intervention group
Group type: COMPARATOR
Intervention: Stored platelets (5 days at 22 degrees C)
Number of subjects: 48
Study 9873262 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelets frozen at -70 degrees C in 5% DMSO
Number of subjects: 48
Study 9873262 — intervention group
Group type: EXPERIMENTAL
Intervention: Lyophilized platelets
Number of subjects: 48
Study 9873262 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelets frozen at -70 degrees C without cryoprotectants
Number of subjects: 48
Study 9873262 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelets stored at 4 degrees C
Number of subjects: 48
Study 7974072 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg trospectomycin sulfate i.m.
Number of subjects: 95
Study 7974072 — intervention group
Group type: COMPARATOR
Intervention: 250 mg ceftriaxone i.m.
Number of subjects: 95
Study 3179203 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 min occlusion with a polypropylene chamber
Number of subjects: 8
Study 3179203 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 min occlusion followed by exposure to ambient conditions for 1 h
Number of subjects: 8
Study 3179203 — intervention group
Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 8
Study 4927813 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (Maxolon)
Number of subjects: 42
Study 31755906 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT adapted for ASD
Number of subjects: 145
Study 31755906 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-of-practice CBT
Number of subjects: 145
Study 31755906 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 145
Study 30884170 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra 100 mg s.c.
Number of subjects: 32
Study 30884170 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra 150 mg s.c.
Number of subjects: 32
Study 30884170 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra 300 mg s.c.
Number of subjects: 32
Study 30884170 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra 100 mg i.v.
Number of subjects: 32
Study 28749480 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine citrate at 10 mg kg‐1 day‐1, increased to 14 or 20 mg kg‐1 day‐1 BID at 36 weeks PMA
Number of subjects: 27
Study 28749480 — intervention group
Group type: COMPARATOR
Intervention: Control group (53 infants)
Number of subjects: 27
Study 25516006 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen/Famotidine combination
Number of subjects: 0
Study 25516006 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 0
Study 23811648 — intervention group
Group type: EXPERIMENTAL
Intervention: Gingival displacement paste (Expasyl displacement paste)
Number of subjects: 16
Study 23811648 — intervention group
Group type: COMPARATOR
Intervention: Gingival retraction cord
Number of subjects: 16
Study 21816979 — intervention group
Group type: EXPERIMENTAL
Intervention: GFT505 at 80 mg/day
Number of subjects: 141
Study 21816979 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study 19890022 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (S)
Number of subjects: 136
Study 19890022 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (M)
Number of subjects: 136
Study 19890022 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin plus Metformin (SM)
Number of subjects: 136
Study 17048576 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative traditional Chinese and Western medicine (ICWM) - Fufang Huangqi granule and lamivudine for at least 24 weeks
Number of subjects: 115
Study 17048576 — intervention group
Group type: COMPARATOR
Intervention: Traditional Chinese medicine (TCM) - Fufang Huangqi granule for at least 24 weeks
Number of subjects: 115
Study 17048576 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (ICWM and TCM)
Number of subjects: 115
Study 17048576 — intervention group
Group type: EXPERIMENTAL
Intervention: ICWM
Number of subjects: 115
Study 17048576 — intervention group
Group type: COMPARATOR
Intervention: TCM
Number of subjects: 115
Study 12944147 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultralight wheelchair (UWC)
Number of subjects: 60
Study 12944147 — intervention group
Group type: COMPARATOR
Intervention: Standard wheelchair (SWC)
Number of subjects: 60
Study 11113832 — intervention group
Group type: EXPERIMENTAL
Intervention: Outreach program for young children with cerebral palsy (monthly training of parents with pictorial guidance manual)
Number of subjects: 85
Study 11113832 — intervention group
Group type: EXPERIMENTAL
Intervention: Center-based mother-child group (daily attendance)
Number of subjects: 85
Study 11113832 — intervention group
Group type: COMPARATOR
Intervention: Health advice (minimal intervention)
Number of subjects: 85
Study 9095008 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral venous lactate (V-LACT)
Number of subjects: 74
Study 9095008 — intervention group
Group type: COMPARATOR
Intervention: Arterial lactate (A-LACT)
Number of subjects: 74
Study 8459913 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadodiamide injection (Gd-DTPA BMA), dosage: 0.1 mmol/kg body weight (0.2 ml/kg)
Number of subjects: 79
Study 8459913 — intervention group
Group type: COMPARATOR
Intervention: Gadopentetate dimeglumine (Gd-DTPA), dosage: 0.1 mmol/kg body weight (0.2 ml/kg)
Number of subjects: 79
Study 8459913 — intervention group
Group type: EXPERIMENTAL
Intervention: Both contrast media
Number of subjects: 79
Study 2949196 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation training
Number of subjects: 24
Study 2949196 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG biofeedback training
Number of subjects: 24
Study 2949196 — intervention group
Group type: COMPARATOR
Intervention: Placebo condition
Number of subjects: 24
Study 31083047 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-CHO availability trial (LOW)
Number of subjects: 8
Study 31083047 — intervention group
Group type: COMPARATOR
Intervention: High-CHO availability trial (HIGH)
Number of subjects: 8
Study 29035068 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal-Assisted Therapy (AAT)
Number of subjects: 19
Study 29035068 — intervention group
Group type: COMPARATOR
Intervention: Control (standard therapy sessions)
Number of subjects: 19
Study 26789124 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Aerobic Training (HIT)
Number of subjects: 16
Study 26789124 — intervention group
Group type: COMPARATOR
Intervention: Sprint Interval Training (SIT)
Number of subjects: 16
Study 24674149 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG Connaught
Number of subjects: 142
Study 24674149 — intervention group
Group type: COMPARATOR
Intervention: BCG Tice
Number of subjects: 142
Study 22424252 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonparticipants (defined as English‐speaking patients who did not engage in the call or refused participation)
Number of subjects: 15000
Study 22424252 — intervention group
Group type: COMPARATOR
Intervention: Participants (those who engaged in the call and accepted participation)
Number of subjects: 15000
Study 19403951 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogurt group (Y) consuming 3 servings of yogurt containing vitamin D per day
Number of subjects: 35
Study 19403951 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogurt group (Y)
Number of subjects: 35
Study 19403951 — intervention group
Group type: COMPARATOR
Intervention: Control group maintaining baseline low-dairy-calcium diet
Number of subjects: 35
Study 19403951 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including yogurt, protein, and carbohydrate groups)
Number of subjects: 35
Study 17299308 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory Structuring Intervention (MSI)
Number of subjects: 34
Study 17299308 — intervention group
Group type: COMPARATOR
Intervention: Supportive listening (control)
Number of subjects: 34
Study 12930254 — intervention group
Group type: EXPERIMENTAL
Intervention: Right atrial linear lesions (RALL)
Number of subjects: 64
Study 12930254 — intervention group
Group type: COMPARATOR
Intervention: Non-right atrial linear lesions (NRALL)
Number of subjects: 64
Study 12930254 — intervention group
Group type: EXPERIMENTAL
Intervention: Interatrial septum pacing (IASP)
Number of subjects: 64
Study 12930254 — intervention group
Group type: EXPERIMENTAL
Intervention: Right atrial appendage pacing (RAAP)
Number of subjects: 64
Study 12930254 — intervention group
Group type: EXPERIMENTAL
Intervention: RALL with IASP
Number of subjects: 64
Study 12930254 — intervention group
Group type: EXPERIMENTAL
Intervention: RALL with RAAP
Number of subjects: 64
Study 12930254 — intervention group
Group type: COMPARATOR
Intervention: NRALL with IASP
Number of subjects: 64
Study 12930254 — intervention group
Group type: COMPARATOR
Intervention: NRALL with RAAP
Number of subjects: 64
Study 11060751 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 0
Study 9087484 — intervention group
Group type: EXPERIMENTAL
Intervention: dideoxyinosine (ddI) monotherapy
Number of subjects: 23
Study 8228774 — intervention group
Group type: EXPERIMENTAL
Intervention: Postcard reminder
Number of subjects: 698
Study 8228774 — intervention group
Group type: COMPARATOR
Intervention: Questionnaire reminder
Number of subjects: 698
Study 8228774 — intervention group
Group type: COMPARATOR
Intervention: Two questionnaires as reminders
Number of subjects: 698
Study 8228774 — intervention group
Group type: COMPARATOR
Intervention: All questionnaires
Number of subjects: 698
Study 3512382 — intervention group
Group type: EXPERIMENTAL
Intervention: Tripotassium dicitrato bismuthate (TDB) tablets
Number of subjects: 80
Study 3512382 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 80
Study 31856902 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment guided by cerebral oxygenation monitoring
Number of subjects: 0
Study 31856902 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study 29443823 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive aerobic exercise training (3 times per week, 150 min·wk for 16 weeks)
Number of subjects: 27
Study 29443823 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive aerobic exercise training
Number of subjects: 27
Study 26546784 — intervention group
Group type: EXPERIMENTAL
Intervention: Social stress test
Number of subjects: 79
Study 26546784 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 79
Study 24981701 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage tailored intervention (ST)
Number of subjects: 1243
Study 24981701 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-stage tailored intervention (NST)
Number of subjects: 1243
Study 24981701 — intervention group
Group type: COMPARATOR
Intervention: Assessment only (controls)
Number of subjects: 1243
Study 22986440 — intervention group
Group type: EXPERIMENTAL
Intervention: linaclotide 290 μg oral once daily
Number of subjects: 800
Study 19909386 — intervention group
Group type: EXPERIMENTAL
Intervention: Duty-cycled bipolar/unipolar radiofrequency (RF) ablation using 8-10 W delivered simultaneously through 2-10 electrodes
Number of subjects: 88
Study 18720044 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron sucrose (600 mg) followed by oral iron sulphate (200 mg daily from week 5)
Number of subjects: 128
Study 18720044 — intervention group
Group type: COMPARATOR
Intervention: Oral iron sulphate (200 mg daily)
Number of subjects: 128
Study 15932366 — intervention group
Group type: EXPERIMENTAL
Intervention: Trefoil factor family‐3 enema (10 mg/mL)
Number of subjects: 16
Study 15932366 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 16
Study 12577194 — intervention group
Group type: EXPERIMENTAL
Intervention: efavirenz + indinavir (EFV+IDV)
Number of subjects: 0
Study 12577194 — intervention group
Group type: EXPERIMENTAL
Intervention: efavirenz + zidovudine + lamivudine (EFV+ZDV+3TC)
Number of subjects: 0
Study 12577194 — intervention group
Group type: EXPERIMENTAL
Intervention: indinavir + zidovudine + lamivudine (IDV+ZDV+3TC)
Number of subjects: 0
Study 10583036 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril 4-8 mg once daily
Number of subjects: 10
Study 10583036 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 8904726 — intervention group
Group type: EXPERIMENTAL
Intervention: Anger management training (6-week program including relaxation training, self-statement modification, and role-play assertiveness training)
Number of subjects: 22
Study 8904726 — intervention group
Group type: EXPERIMENTAL
Intervention: Anger management training
Number of subjects: 22
Study 8904726 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 22
Study 1806620 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 0
Study 1806620 — intervention group
Group type: COMPARATOR
Intervention: Lorazepam
Number of subjects: 0
Study 6576263 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 16
Study 6576263 — intervention group
Group type: COMPARATOR
Intervention: Saline or Naloxone (Control)
Number of subjects: 16
Study 30791771 — intervention group
Group type: EXPERIMENTAL
Intervention: Linaclotide (72 µg, 145 µg, 290 µg)
Number of subjects: 3853
Study 30791771 — intervention group
Group type: EXPERIMENTAL
Intervention: Linaclotide (open-label)
Number of subjects: 3853
Study 30791771 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3853
Study 28095924 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonolysis (continual transcranial Doppler monitoring, TCD) using a 2‐MHz diagnostic probe with maximal diagnostic energy
Number of subjects: 704
Study 28095924 — intervention group
Group type: COMPARATOR
Intervention: Control (sham procedure)
Number of subjects: 704
Study 28095924 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonolysis (continual transcranial Doppler monitoring, TCD)
Number of subjects: 704
Study 27354646 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel plus Cisplatin (DP) - Docetaxel 70 mg/m²; Cisplatin 60 mg/m²; administered every 28 days
Number of subjects: 64
Study 27354646 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel plus Cisplatin (DP)
Number of subjects: 64
Study 25065090 — intervention group
Group type: EXPERIMENTAL
Intervention: Kegel exercise with concentration therapy
Number of subjects: 135
Study 25065090 — intervention group
Group type: COMPARATOR
Intervention: Kegel exercise alone
Number of subjects: 135
Study 23247938 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg/wk
Number of subjects: 154
Study 23247938 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg every other week (EOW)
Number of subjects: 154
Study 23247938 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study 23247938 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg EOW
Number of subjects: 154
Study 19430082 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily iron-folate (IFA) supplementation (100 mg elemental iron + 0.5 mg folic acid daily for one year)
Number of subjects: 163
Study 19430082 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice weekly iron-folate (IFA) supplementation (100 mg elemental iron + 0.5 mg folic acid twice weekly for one year)
Number of subjects: 163
Study 19430082 — intervention group
Group type: EXPERIMENTAL
Intervention: Once weekly iron-folate (IFA) supplementation (100 mg elemental iron + 0.5 mg folic acid once weekly for one year)
Number of subjects: 163
Study 19430082 — intervention group
Group type: COMPARATOR
Intervention: Control group (no IFA supplementation)
Number of subjects: 163
Study 17341587 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lignocaine hydrochloride
Number of subjects: 22
Study 17341587 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 22
Study 12502652 — intervention group
Group type: COMPARATOR
Intervention: No snack (placebo)
Number of subjects: 15
Study 12502652 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard snack (two starch + one protein exchange)
Number of subjects: 15
Study 12502652 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein snack
Number of subjects: 15
Study 12502652 — intervention group
Group type: EXPERIMENTAL
Intervention: Any snack (standard or protein)
Number of subjects: 15
Study 12502652 — intervention group
Group type: EXPERIMENTAL
Intervention: HS glucose >10 mmol/l
Number of subjects: 15
Study 10475722 — intervention group
Group type: EXPERIMENTAL
Intervention: Thioridazine (Y: 50 mg; O: 25 mg)
Number of subjects: 26
Study 10475722 — intervention group
Group type: EXPERIMENTAL
Intervention: Remoxipride (Y: 100 mg; O: 50 mg)
Number of subjects: 26
Study 10475722 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 10475722 — intervention group
Group type: EXPERIMENTAL
Intervention: Thioridazine
Number of subjects: 26
Study 8814044 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy challenge (powdered soy formula in fruit juice)
Number of subjects: 704
Study 8814044 — intervention group
Group type: COMPARATOR
Intervention: Placebo (rice or corn flour)
Number of subjects: 704
Study 2052306 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine hydrochloride 0.75% (Marcaine)
Number of subjects: 50
Study 2052306 — intervention group
Group type: COMPARATOR
Intervention: Balanced salt solution (placebo)
Number of subjects: 50
Study 7104167 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug with non-linear release (NLR)
Number of subjects: 36
Study 7104167 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug with linear release (LR)
Number of subjects: 36
Study 7104167 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 7104167 — intervention group
Group type: COMPARATOR
Intervention: Drug-free control
Number of subjects: 36
Study 31825466 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine 30 mg orally once daily for 24 weeks
Number of subjects: 120
Study 31825466 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 30726969 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox 250 mg before oral glucose test
Number of subjects: 2
Study 30726969 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox 250 mg before and during metabolic study
Number of subjects: 2
Study 27821724 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous CD34+ cells (minimum 10 mol/L±20% cells), N=78
Number of subjects: 161
Study 27821724 — intervention group
Group type: COMPARATOR
Intervention: Diluent alone, N=83
Number of subjects: 161
Study 24670072 — intervention group
Group type: EXPERIMENTAL
Intervention: Worksite social support
Number of subjects: 958
Study 23980925 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Family‐Centred Care intervention (n = 74)
Number of subjects: 134
Study 23980925 — intervention group
Group type: COMPARATOR
Intervention: Standard care group (n = 60)
Number of subjects: 134
Study 21601248 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin plus solifenacin 2.5 mg (TAM+SOL)
Number of subjects: 638
Study 21601248 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin plus solifenacin 5 mg (TAM+SOL)
Number of subjects: 638
Study 21601248 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin plus placebo (TAM+PBO)
Number of subjects: 638
Study 18501530 — intervention group
Group type: EXPERIMENTAL
Intervention: IG-IMRT (image-guided intensity-modulated radiotherapy)
Number of subjects: 25
Study 18501530 — intervention group
Group type: COMPARATOR
Intervention: IMRT (intensity-modulated radiotherapy)
Number of subjects: 25
Study 18501530 — intervention group
Group type: EXPERIMENTAL
Intervention: IG-IMRT
Number of subjects: 25
Study 16396628 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 26
Study 16396628 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 16396628 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic renal failure
Number of subjects: 26
Study 16236919 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking reduction with nicotine replacement therapy (nicotine gum and patch), required to reduce smoking by 25% for 2 weeks, 50% for 2 weeks, and 75% during the final 2 weeks.
Number of subjects: 151
Study 16236919 — intervention group
Group type: COMPARATOR
Intervention: Ad libitum smoking for 6 weeks (control group).
Number of subjects: 151
Study 10493476 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound surveillance
Number of subjects: 2257
Study 10493476 — intervention group
Group type: COMPARATOR
Intervention: Control of blood pressure and cessation of smoking
Number of subjects: 2257
Study 8740120 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (100 mg twice daily for 3-5 days)
Number of subjects: 358
Study 8740120 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 358
Study 1833892 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone 3 mg/kg orally
Number of subjects: 10
Study 7042179 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre‐operative radiotherapy combined with daily intravenous fluorouracil during the first 4 days of irradiation followed by surgery (C)
Number of subjects: 143
Study 7042179 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre‐operative radiotherapy followed by surgery (R)
Number of subjects: 143
Study 7042179 — intervention group
Group type: COMPARATOR
Intervention: Surgery only (S)
Number of subjects: 143